Omaveloxolone is an activator of Nrf2 and restores mitochondrial function ex vivo in fibroblasts from people with FRDA, but there is no evidence that it can increase the levels of FXN gene expression and frataxin protein. This evidence concerns the gene NFE2L2 and Friedreich ataxia.